What does this study add?

• 32% of patients reported freedom from headache at 2 hours following ubrogepant treatment for one or more attacks.
• 12% of patients said ubrogepant provided consistent, complete headache freedom at 2 hours.
• 73% of patients reported pain relief at 2 hours following ubrogepant treatment for one or more attacks.
• 27% of patients said ubrogepant provided consistent pain relief at 2 hours.
• The most common adverse events reported were fatigue, nausea, dry mouth, and constipation.
• Preliminary results for rimegepant and lasmiditan are still under analysis.